DAWES KAREN A

SEC Form 4 insider trading activity

DAWES KAREN A has filed 3 SEC Form 4 filings (3 transaction rows) across 2 companies, including BRNS, RGEN, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Sep 9, 2026.

On the most recent filing, DAWES KAREN A is listed as Director at REPLIGEN CORP. Inside the rolling window, DAWES KAREN A reported no open-market purchases and 1 open-market sale totaling $44K in RGEN.

Companies traded

Other insiders at BRNS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$44K

reported sales (SEC code S)

Companies

2

in the rolling window

Source
RGEN
DAWES KAREN A
Sale$44KDec 18SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has DAWES KAREN A made?

DAWES KAREN A has filed 3 SEC Form 4 filings (3 transaction rows) across 2 companies, including BRNS, RGEN since 2025.

Which companies does DAWES KAREN A trade?

DAWES KAREN A has filed SEC Form 4 disclosures for 2 companies, including BRNS, RGEN.

When was DAWES KAREN A's most recent SEC Form 4 filing?

DAWES KAREN A's most recent SEC Form 4 filing on Tracefour is dated Sep 9, 2026.

What is DAWES KAREN A's total buy and sell value in the current window?

Inside the rolling retention window, DAWES KAREN A bought $0 and sold $44K based on SEC Form 4 filings.

What was DAWES KAREN A's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 275 RGEN shares on 2025-12-17, worth $44K, per SEC Form 4 filings.